NCT00698555View on ClinicalTrials.gov

Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y

PHASE2CompletedINTERVENTIONAL

Enrollment

163

Participants

Timeline

Start Date

March 31, 1997

Primary Completion Date

May 31, 1998

Conditions

Hepatitis B

Interventions

BIOLOGICAL

HBV-MPL vaccine

5 different formulations, 2-dose intramuscular injection

BIOLOGICAL

Engerix™-B

3-dose intramuscular injection

Trial Locations (1)

Unknown

GSK Clinical Trials Call Center, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00698555 - Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y | Biotech Hunter | Biotech Hunter